1/12/2006 – With its treatment for a bleeding disorder moving into Phase I clinical trials, antibody specialist Symphogen A/S has closed a $25 million (EUR20.7 million) Series D round. [ full story ]
1/12/2006 – With its treatment for a bleeding disorder moving into Phase I clinical trials, antibody specialist Symphogen A/S has closed a $25 million (EUR20.7 million) Series D round. [ full story ]
